Secondary prevention in coronary artery disease. Achieved goals and possibilities for improvements

被引:9
|
作者
Libungan, Berglind [1 ]
Stensdotter, Lillemor [1 ]
Hjalmarson, Agneta [1 ]
Attebring, Mona From [2 ]
Lindqvist, Jonny [1 ]
Back, Maria [3 ]
Herlitz, Johan [1 ,4 ]
机构
[1] Sahlgrens Univ Hosp, Dept Mol & Clin Med, Inst Med, SE-41345 Gothenburg, Sweden
[2] Linnaeus Univ, Sch Hlth & Caring Sci, S-35195 Vaxjo, Sweden
[3] Sahlgrens Univ Hosp, Physiotherapy Dept, Inst Med, SE-41345 Gothenburg, Sweden
[4] Univ Coll Boras, Boras, Sweden
关键词
Coronary artery disease; Myocardial infarction; Angina pectoris; Secondary prevention; MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; EUROPEAN COUNTRIES; HEART-DISEASE; RISK-FACTORS; PARTICIPANTS; MORTALITY; RAMIPRIL; PROGRAMS; SWEDEN;
D O I
10.1016/j.ijcard.2011.04.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To describe presence of risk indicators of recurrence 6 months after hospitalisation due to coronary artery disease at a university clinic. Methods: The presence of risk indicators, including tobacco use, lipid levels, blood pressure and glucometabolic status, including 24-hour blood pressure monitoring and an oral glucose-tolerance test, was analysed. Results: Of 1465 patients who were screened, 402 took part in the survey (50% previous myocardial infarction and 50% angina pectoris). Mean age was 64 years (range 40-85 years) and 23% were women. Present medications were: lipid lowering drugs (statins; 94%), beta-blockers (85%), aspirin or warfarin (100%) and ACE-inhibitors or angiotensin II blockers (66%). Values above target levels recommended in guidelines were: a) low density lipoprotein (LDL) in 40%; b) mean blood pressure (day or night) in 38% and c) smoking in 13%. Of all patients, 66% had at least one risk factor (LDL or blood pressure above target levels or current smoking). An abnormal glucose-tolerance test was found in 59% of patients without known diabetes. If no history of diabetes, 85% had either LDL or blood pressure above target levels, current smoking or an abnormal glucose-tolerance test. However, with treatment intensification to patients with elevated risk factors 56% reached target levels for blood pressure and 79% reached target levels for LDL. Conclusion: Six months after hospitalisation due to coronary artery disease, despite the high use of medication aimed at prophylaxis against recurrence, the majority were either above target levels for LDL or blood pressure or continued to smoke. (c) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:18 / 24
页数:7
相关论文
共 50 条
  • [41] Secondary prevention antibiotic treatment trials for coronary artery disease
    Grayston, JT
    [J]. CIRCULATION, 2000, 102 (15) : 1742 - 1743
  • [42] Is there a gender gap in secondary prevention of coronary artery disease in Turkey?
    Kocyigit, Duygu
    Tokgozoglu, Lale
    Kayikcioglu, Meral
    Altay, Servet
    Aydogdu, Sinan
    Barcin, Cem
    Bostan, Cem
    Cakmak, Huseyin Altug
    Catakoglu, Alp Burak
    Emet, Samim
    Ergene, Oktay
    Kalkan, Ali Kemal
    Kaya, Baris
    Kaya, Cansin
    Kaymaz, Cihangir
    Koylan, Nevrez
    Kultursay, Hakan
    Oguz, Aytekin
    Ozpelit, Ebru
    Unlu, Serkan
    [J]. TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2018, 46 (08): : 683 - 691
  • [43] Inflammation: the next target for secondary prevention in coronary artery disease
    Kazi, Samia
    Chong, James J. H.
    Chow, Clara K.
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2024, 220 (03) : 115 - 120
  • [44] Secondary prevention of coronary artery disease in contemporary clinical practice
    Jankowski, Piotr
    Czarnecka, Danuta
    Wolfshaut-Wolak, Renata
    Lysek, Radoslaw
    Lukaszewska, Anna
    Bogacki, Piotr
    Grodecki, Janusz
    Mirek-Bryniarska, Ewa
    Nessler, Jadwiga
    Podolec, Piotr
    Kawecka-Jaszcz, Kalina
    Pajak, Andrzej
    [J]. CARDIOLOGY JOURNAL, 2015, 22 (02) : 219 - 226
  • [45] The role of antiplatelet therapy in the secondary prevention of coronary artery disease
    Behan, Miles W.
    Chew, Derek P.
    Aylward, Philip E.
    [J]. CURRENT OPINION IN CARDIOLOGY, 2010, 25 (04) : 321 - 328
  • [46] Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease
    Cheng, Judy W.
    [J]. JOURNAL OF MANAGED CARE PHARMACY, 2007, 13 (04): : 326 - 336
  • [47] Secondary prevention for coronary artery disease: are we following the guidelines?
    I. A. A. Syed
    A. Riaz
    A. Ryan
    M. O. Reilly
    [J]. Irish Journal of Medical Science, 2010, 179 : 535 - 537
  • [48] Comorbidities, costs and therapeutic goals achieved in the secondary prevention of the primary health
    Sicras, A.
    Navarro, R.
    Llopart Lopez, J. R.
    F Bobadilla, J.
    Garcia, M.
    Gonzalez, P.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A350 - A351
  • [49] Secondary prevention in coronary heart disease. Fact: Lowering cholesterol saves lives
    McKenna, CJ
    Sugrue, DD
    [J]. IRISH MEDICAL JOURNAL, 1995, 88 (06) : 191 - 191
  • [50] Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
    Gaspoz, J
    Coxson, PG
    Goldman, PA
    Williams, LW
    Kuntz, KM
    Hunink, MGM
    Goldman, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (23): : 1800 - 1806